NR and NMN treatments were ex vivo tested on RA–PBMCs, thus highlighting NAD+ amount increasing via NAMPT and nicotinamide mononucleotide adenylyl transferase (NMNAT), and reducing the proinflammatory, pro-oxidative and pro-apoptosis in RA patients [136]. Here, NMNAT1 is linked to rheumatoid arthritis.